Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Meagan Jacoby, MD, Reetom Bera, Theresa Fletcher, Mark A. Fiala, BS, Kathryn Trinkaus, PhD, John F. DiPersio, MD PhD, Keith E. Stockerl-Goldstein, MD, Mark A. Schroeder, MD, Daniel C. Link, MD, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 2146.

https://doi.org/10.1182/blood-2018-99-115603

Published: 2018

Journal Articles

Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

Geoffrey L. Uy, MD, Michael P Rettig, PhD, Theresa Fletcher, Peter A Riedell, MD, Keith E. Stockerl-Goldstein, MD, Armin Ghobadi, MD, Meagan Jacoby, MD PhD, Amanda F. Cashen, MD, Rizwan Romee, MD, Iskra Pusic, MD, Camille N. Abboud, MD, Mark A. Schroeder, MD, Ravi Vij, MDMBA, Peter Westervelt, MDPhD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 816.

https://doi.org/10.1182/blood.V130.Suppl_1.816.816

Published: 2017

Journal Articles

Phase II Study of Propylene Glycol-Free Melphalan (Evomela) Combined with Carmustine, Etoposide, and Cytarabine (BEAM) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

Amanda F. Cashen, MD, Kendall Gosch, BA, Theresa Fletcher, MS, Connie Ceriotti, RN, BSN, Armin Ghobadi, MD, Ravi Vij, MD, Keith Stockerl-Goldstein, MD, John F Dipersio, MD PhD, Camille N Abboud, MD

Blood (2015) 126 (23): 3196.

https://doi.org/10.1182/blood.V126.23.3196.3196

Published: 2015

Journal Articles

A Study of High Dose Lenalidomide Induction and Low Dose Lenalidomide Maintenance for Patients with Hypomethylating Agent Refractory MDS

Mathew A. Cherian, MD, Raoul Tibes, MD PhD, Theresa Fletcher, MS, Mark A. Fiala, BS, CCRP, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD, Keith E. Stockerl-Goldstein, MD, Meagan Jacoby, MD PhD, Amanda F. Cashen, MD, John F. DiPersio, MD PhD, Ravi Vij, MD

Blood (2014) 124 (21): 1931.

https://doi.org/10.1182/blood.V124.21.1931.1931

Published: 2014

Journal Articles

A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia

Lukas D. Wartman, MD, Mark A. Fiala, BS, CCRP, Emily Hawkins, BS, Theresa Fletcher, MS, Melissa Allen, Amanda F. Cashen, MD, John F. DiPersio, MD PhD, Meagan Jacoby, MD PhD, Keith E. Stockerl-Goldstein, MD, Iskra Pusic, MD, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD, Ravi Vij, MBBS, MD

Blood (2014) 124 (21): 5292.

https://doi.org/10.1182/blood.V124.21.5292.5292

Published: 2014

Journal Articles

A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma

Tzu-Fei Wang, MD, Mark A. Fiala, BS, CCRP, Ningying Wu, PhD, Theresa Fletcher, Camille N. Abboud, MD, Amanda F. Cashen, MD, John F. Dipersio, MD, PhD, Geoffrey L. Uy, MD, Peter Westervelt, MD, PhD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MD

Blood (2013) 122 (21): 5492.

https://doi.org/10.1182/blood.V122.21.5492.5492

Published: 2013

NARROW

A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

Phase II Study of Propylene Glycol-Free Melphalan (Evomela) Combined with Carmustine, Etoposide, and Cytarabine (BEAM) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

A Study of High Dose Lenalidomide Induction and Low Dose Lenalidomide Maintenance for Patients with Hypomethylating Agent Refractory MDS

A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia

A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

Phase II Study of Propylene Glycol-Free Melphalan (Evomela) Combined with Carmustine, Etoposide, and Cytarabine (BEAM) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

A Study of High Dose Lenalidomide Induction and Low Dose Lenalidomide Maintenance for Patients with Hypomethylating Agent Refractory MDS

A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia

A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only